Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
Two women (aged 46 and 56 years) developed annular erythema on their sun-exposed skin, including their forearms and faces, after biweekly i.v. administration of paclitaxel for 3-4 months to treat breast cancer. Both cases showed interface changes of basal keratinocytes and high titers of serum anti-SSA/Ro antibody. The diagnoses of paclitaxel-induced cutaneous lupus erythematosus (LE) were made because the skin eruptions cleared rapidly within 3 weeks after the paclitaxel treatment was discontinued. Paclitaxel is proposed to be a causative agent that can provoke cutaneous LE.
Adachi
Atsuko
A
Department of Dermatology, Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan. adc4954@ybb.ne.jp
Horikawa
Tatsuya
T
D000974:Antibodies, Antinuclear / Q000097:blood*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001132:Arm / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000276:immunology; D012867:Skin / Q000473:pathology
D000974:Antibodies, Antinuclear; D000972:Antineoplastic Agents, Phytogenic; C035356:SS-A antibodies; D017239:Paclitaxel